A 1-Year Safety Study of OTO-104 in Subjects With Unilateral Meniere's Disease Located in United Kingdom
Launched by OTONOMY, INC. · Oct 9, 2014
Trial Information
Current as of June 15, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria includes, but is not limited to:
- • Subject has a diagnosis of definite unilateral Meniere's disease.
- • Subject agrees to maintain their current standard of care treatments for Meniere's disease while on-study.
- Exclusion Criteria includes, but is not limited to:
- • Subject is pregnant or lactating.
- • Subject has a history of immunodeficiency disease.
- • Subject has a history of previous endolymphatic sac surgery.
- • Subject has a history of previous use of intratympanic gentamicin in the affected ear.
- • Subject has a history of drop attacks.
- • Subject has experienced an adverse reaction to intratympanic injection of steroids.
About Otonomy, Inc.
Otonomy, Inc. is a biopharmaceutical company focused on developing innovative therapeutics for the treatment of ear disorders. With a commitment to advancing patient care, Otonomy leverages its proprietary drug delivery technologies to address unmet medical needs in conditions such as hearing loss and chronic ear diseases. The company's robust pipeline includes both clinical and preclinical programs aimed at providing effective and long-lasting treatment options. Otonomy is dedicated to improving the lives of patients through scientific excellence and a patient-centered approach to drug development.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Oxford, , United Kingdom
Cambridge, , United Kingdom
Bristol, , United Kingdom
Dorset, , United Kingdom
Norfolk, , United Kingdom
Gloucester, , United Kingdom
Berkshire, , United Kingdom
Birmingham, , United Kingdom
Birmingham, , United Kingdom
Bucks, , United Kingdom
Leicestershire, , United Kingdom
London, , United Kingdom
London, , United Kingdom
Sheffield, , United Kingdom
Staffordshire, , United Kingdom
Patients applied
Trial Officials
Carl LeBel, PhD
Study Chair
Otonomy, Inc.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials